Identification of a new HLA-A2–restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma
- 30 April 2006
- journal article
- Published by Elsevier BV in Experimental Hematology
- Vol. 34 (4), 486-496
- https://doi.org/10.1016/j.exphem.2006.01.008
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Generation of Potent Antitumor CTL from Patients with Multiple Myeloma Directed against HM1.24Clinical Cancer Research, 2005
- Post‐transplantation tumour load in bone marrow, as assessed by quantitative ASO‐PCR, is a prognostic parameter in multiple myelomaBritish Journal of Haematology, 2004
- A gene atlas of the mouse and human protein-encoding transcriptomesProceedings of the National Academy of Sciences of the United States of America, 2004
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapyLeukemia, 2003
- Reactive plasmacytoses, a model for studying the biology of human plasma cell progenitors and precursorsThe Hematology Journal, 2000
- Molecular Cloning and Characterization of a Surface Antigen Preferentially Overexpressed on Multiple Myeloma CellsBiochemical and Biophysical Research Communications, 1999
- Gapped BLAST and PSI-BLAST: a new generation of protein database search programsNucleic Acids Research, 1997
- Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).The Journal of Experimental Medicine, 1996